世界中医药
文章摘要
引用本文:王田田1,2,宋婉婷1,2,蔡绮薇1,3,倪蒙蒙4,路斯娴1,徐冰1,2,3.2014—2018年我国口服中成药抽检结果的大数据分析与思考[J].世界中医药,2020,(22):.  
2014—2018年我国口服中成药抽检结果的大数据分析与思考
Big Data Analysis and Thinking of National Sampling and Testing Results of Oral Chinese Patent Medicines from 2014 to 2018
投稿时间:2019-04-18  
DOI:10.3969/j.issn.1673-7202.2020.22.028
中文关键词:  药品抽检  大数据  中成药  口服固体制剂  口服液体制剂
English Keywords:Drug sampling and testing  Big data  Chinese patent medicines  Oral solid preparations  Oral liquid preparations
基金项目:国家中药标准化项目(ZYBZH-C-QIN-45);北京中医药大学自主选题项目(2019-JYB-JS-015)
作者单位
王田田1,2,宋婉婷1,2,蔡绮薇1,3,倪蒙蒙4,路斯娴1,徐冰1,2,3 1 北京中医药大学中药信息学系北京102400
2 北京市科委中药生产过程控制与质量评价北京市重点实验室北京102400
3 教育部中药制药与新药开发关键技术工程研究中心北京102400
4 山东步长制药股份有限公司菏泽274000 
摘要点击次数: 451
全文下载次数: 0
中文摘要:
      目的:基于国家药品抽检结果数据,分析评价我国中成药产品质量状况,为相关监管部门和药品生产企业提供参考。方法:收集2014—2018年间,国家药品监督管理局和各省局公布的药品抽检通告,对5 433条不合格批次数据进行归类统计,重点分析口服固体和口服液体中成药制剂的质量问题。结果:中成药片剂、胶囊剂的不合格批次数较多,分别占口服剂型不合格批次总数的47.60%和26.47%,其次是丸剂与颗粒剂。检查项是口服中成药最常见的不合格项,不合格内容以装(重)量差异、水分和微生物限度为主。结论:近5年间我国中成药质量状况总体乐观,周期性药品抽检结果回顾有利于发现药品质量问题趋势,为药品质量监督水平和药品全产业链质量控制水平的提高提供有益参考。
English Summary:
      Based on the national drug sampling results data, to analyze and evaluate the quality of Chinese patent medicine products in my country, and provide references for relevant regulatory authorities and drug manufacturers. Methods:The drug sampling notices issued by the national and provincial drug administrations from 2014 to 2018 were collected. Classification and statistics of 5 433 unqualified batch data were conducted. And we focused on the quality problems of oral solid and oral liquid Chinese patent medicine preparations. Results:There were many unqualified batches of Chinese patent medicine tablets and capsules, accounting for 47.60% and 26.47% of the total number of unqualified batches of oral dosage forms, followed by pills and granules. The inspection items were the most common unqualified items of oral Chinese patent medicines, and the unqualified contents were mainly the difference in loading (weight), moisture and microbial limits. Conclusion:In the past five years, the quality of Chinese patent medicines in my country is generally optimistic. The review of the results of periodic drug inspections is conducive to discovering the trend of drug quality problems and provides a useful reference for the improvement of the level of drug quality supervision and the level of quality control of the entire drug industry chain.
查看全文  查看/发表评论  下载PDF阅读器